Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19329100 | 1.00 | PTPN1 (0.71) | PTPN1HDAC8 | |
| SCHEMBL1201702 | 0.95 | PTPN1 (0.65) | PTPN1HDAC8 | |
| SCHEMBL16879298 | 0.90 | PTPN1 (0.57) | PTPN1HDAC8 | |
| SCHEMBL16879299 | 0.90 | PTPN1 (0.57) | PTPN1HDAC8 | |
| SCHEMBL7473706 | 0.89 | HDAC8 (0.58) | PTPN1HDAC8 | |
| SCHEMBL7473700 | 0.89 | HDAC8 (0.58) | PTPN1HDAC8 | |
| SCHEMBL5126474 | 0.87 | PTPN1 (0.67) | PTPN1HDAC8 | |
| SCHEMBL3995398 | 0.87 | PTPN1 (0.64) | PTPN1HDAC8 | |
| SCHEMBL3990059 | 0.87 | PTPN1 (0.64) | PTPN1HDAC8 | |
| SCHEMBL18929509 | 0.87 | PTPN1 (0.69) | PTPN1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426648-B1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2021-05-12 | — | — | EP | disclosed |
| EP-3426648-B1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2021-05-12 | — | — | EP | disclosed |
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD (AU) | 2019-09-24 | — | — | US | disclosed |
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD (AU) | 2019-09-24 | — | — | US | disclosed |
| US-20190071425-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2019-03-07 | — | — | US | disclosed |
| US-20190071425-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2019-03-07 | — | — | US | disclosed |
| EP-3426648-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | Ctxt Pty Ltd (AU) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153513-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153513-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| EP-1045844-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1045844-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2000-10-25 | — | — | EP | disclosed |
| US-5932590-A | PEPTIDOMIMETIC IMIDAZOLYL-CONTAINING 1,2,3,4-TETRAHYDRO-QUINOLINES OR AN ANALOGOUS 3-BENZAZEPINES; ANTICARCINOGENIC AND-PROLIFERATIVE AGENTS; POLYCYSTIC KIDNEY DISEASE; RESTENOSIS PREVENTION; HEPATITIS; RETINAL VASCULARZATION | MERCK & CO., INC. (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1999028314-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071425-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PTPN1 4467/4885HDAC8 707/4885 |
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | PTPN1 4467/4885HDAC8 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.